SCHEMBL5289878

SCHEMBL5289878

CCC(=O)Oc1ccc(-c2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.69
SMN1; SMN2 Q16637 6/20 0.59
KMT2A Q03164 6/20 0.59
ESR1 P03372 2/20 0.59
HIF1A Q16665 2/20 0.59
RECQL P46063 1/20 0.59
MAPT P10636 6/20 0.57
RAB9A P51151 5/20 0.57
NPC1 O15118 4/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
TP53 P04637 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
LMNA P02545 3/20 0.51
HTT P42858 2/20 0.51
ASAH1 Q13510 1/20 0.50
MEN1 O00255 3/20 0.49
CYP1A2 P05177 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9171166 0.92 KMT2A (0.68) ELANESMN1; SMN2KMT2AESR1HIF1A
SCHEMBL13855298 0.90 ELANE (0.58) ELANESMN1; SMN2KMT2AESR1HIF1A
SCHEMBL12751387 0.88 ELANE (0.59) ELANESMN1; SMN2KMT2AESR1HIF1A
SCHEMBL9799566 0.88 ELANE (0.72) ELANESMN1; SMN2KMT2AESR1HIF1A
Benzene SCHEMBL28089483 0.88 ELANE (0.72) ELANESMN1; SMN2KMT2AESR1HIF1A
SCHEMBL45119 0.88 ELANE (0.72) ELANESMN1; SMN2KMT2AESR1HIF1A
SCHEMBL17028724 0.86 ELANE (0.70) ELANESMN1; SMN2KMT2AESR1HIF1A
Ammonia Solution, Strong SCHEMBL22042017 0.86 ELANE (0.70) ELANESMN1; SMN2KMT2AESR1HIF1A
Methane SCHEMBL6301524 0.86 ELANE (0.70) ELANESMN1; SMN2KMT2AESR1HIF1A
SCHEMBL8467278 0.86 ELANE (0.70) ELANESMN1; SMN2KMT2AESR1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120157577-A Application of tetra-n-butyl ammonium bromide as catalyst in catalyzing reaction of methoxyl aromatic hydrocarbon and acyl bromide 皖南医学院 2025-06-17 CN disclosed
US-20110091808-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-21 US disclosed
US-20110091808-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-21 US disclosed
EP-1828144-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI Pharmaceuticals, Inc. (US) 2007-09-05 EP disclosed
WO-2006053342-A2 INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS OSI PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed
CN-1240386-C Inhibitors of matrix metalloproteinases and tumor necrosis factor XIANJIN GENE CO LTD (CN) 2006-02-08 CN disclosed
CN-1723903-A Matrix metalloproteinase and tumor necrosis factor inhibitors ADVANCED GENE TECHNOLOGY CORP (CN) 2006-01-25 CN disclosed
CN-1440751-A Inhibitors of matrix metalloproteinases and tumor necrosis factor XIANJIN GENE CO LTD (CN) 2003-09-10 CN disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed
EP-0874808-A1 BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES Abbott Laboratories (US) 1998-11-04 EP disclosed
WO-1997018188-A1 BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES ABBOTT LABORATORIES (US) 1997-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110091808-A1 PHOTORESIST COMPOSITION ASIC1, ASIC3, SUN2 ELANE 1355/4885SMN1; SMN2 4235/4885KMT2A 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.